Menotrophin Ferring

Menotrophin, the active ingredient in Menotrophin Ferring, is a Gonadotropin (FSH/LH) preparation presented as a subcutaneous injectable for use in reproductive hormone therapy. It is used to stimulate follicular development and ovulation in women with anovulatory infertility and in assisted reproductive technology cycles.

GNH USA supplies Menotrophin Ferring as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide.

Menotrophin is employed in reproductive endocrinology to promote follicular growth and ovulation in several clinical scenarios.

- Anovulatory infertility: induces follicular development and ovulation in women who do not ovulate spontaneously. - In vitro fertilisation (IVF) cycles: supports controlled ovarian stimulation to obtain multiple mature oocytes. - Polycystic ovary syndrome (PCOS) ovulation induction: facilitates follicular maturation and timed ovulation.

Menotrophin may cause a range of adverse reactions, most of which are related to its hormonal activity and injection route.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the subcutaneous site. - Nausea or abdominal discomfort: transient gastrointestinal upset. - Headache: mild to moderate intensity. - Mild ovarian hyperstimulation: enlarged ovaries without severe symptoms. - Mood changes: irritability or emotional lability.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): rapid weight gain, ascites, or respiratory distress. - Multiple pregnancy: increased risk of twins or higher-order gestations. - Allergic reaction or anaphylaxis: rash, swelling, or breathing difficulty. - Thromboembolic events: rare clot formation. - Ectopic pregnancy: implantation outside the uterine cavity.

Before initiating Menotrophin therapy, clinicians should consider several safety measures.

- Monitor ovarian response: use serial ultrasound and estradiol measurements. - Avoid use in known hypersensitivity: discontinue if allergic signs appear. - Assess pituitary function: ensure adequate endogenous gonadotropin reserve. - Use caution with ovarian cysts: evaluate size and risk before stimulation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menotrophin can interact with other hormonal agents and medications that affect ovarian response.

Major Interactions (Avoid): - GnRH agonists: may increase risk of severe ovarian hyperstimulation. - hCG therapy: can exacerbate ovarian response and heighten hyperstimulation risk. - Estrogen‑containing contraceptives: may diminish Menotrophin efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for bleeding if ovarian cyst rupture occurs. - Thyroid hormone therapy: observe thyroid function as hormonal shifts may occur. - Corticosteroids: may alter hormone metabolism and affect response.